{"title":"[New treatments for cutaneous lupus].","authors":"François Chasset","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>NEW TREATMENTS FOR CUTANEOUS LUPUS. Cutaneous lupus may present as an isolated skin disease, or may be associated with systemic lupus, of which it is one of the most frequent manifestations. The management of this disease is poorly codified, and treatment depends on the severity of the disease, whether or not it is associated with systemic lupus, and many other factors. Synthetic antimalarials, in particular hydroxychloroquine, are the cornerstone of treatment. In recent years, several molecules have shown results that are both highly promising and disappointing. A major new development is the granting of European marketing authorization for anifrolumab in systemic lupus in 2022, which seems to be producing particularly interesting results in skin involvement.</p>","PeriodicalId":94123,"journal":{"name":"La Revue du praticien","volume":"75 2","pages":"123-130"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"La Revue du praticien","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
NEW TREATMENTS FOR CUTANEOUS LUPUS. Cutaneous lupus may present as an isolated skin disease, or may be associated with systemic lupus, of which it is one of the most frequent manifestations. The management of this disease is poorly codified, and treatment depends on the severity of the disease, whether or not it is associated with systemic lupus, and many other factors. Synthetic antimalarials, in particular hydroxychloroquine, are the cornerstone of treatment. In recent years, several molecules have shown results that are both highly promising and disappointing. A major new development is the granting of European marketing authorization for anifrolumab in systemic lupus in 2022, which seems to be producing particularly interesting results in skin involvement.